David Mehalick serves as Executive at Coeptis Therapeutics Inc., where they oversee executive responsibilities. Since joining the company, David Mehalick has executed 5 insider transactions totaling $16.7K, demonstrating a bullish approach to their equity position. Their most recent transaction on Jan 8, 2024 involved purchasing 6,000 shares valued at $4.0K.
David Mehalick currently holds 2,768,611 shares of Coeptis Therapeutics Inc. (COEP), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, David Mehalick has been a net buyer of COEP stock. They have purchased $16.7K and sold $0 worth of shares.
David Mehalick's most recent insider trade was on Jan 8, 2024, when they purchased 6,000 shares at $0.67 per share.
Get notified when new Form 4 filings are submitted
| $0.66 |
| Discretionary |
| Jan 5, 2024 | COEP | $3.5K | Purchase | 5,050 | $0.69 | Discretionary |
| Dec 7, 2023 | COEP | $0 | Gift | 700,000 | $N/A | Discretionary |
| Nov 16, 2021 | COEP | $0 | Sale | 1,200,000 | $N/A | Discretionary |